BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Koola MM, Praharaj SK, Pillai A. Galantamine-Memantine Combination as an Antioxidant Treatment for Schizophrenia. Curr Behav Neurosci Rep 2019;6:37-50. [PMID: 32601581 DOI: 10.1007/s40473-019-00174-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Veselinović T, Neuner I. Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia. CNS Drugs 2022. [PMID: 35831706 DOI: 10.1007/s40263-022-00935-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
2 Bai MY, Lovejoy DB, Guillemin GJ, Kozak R, Stone TW, Koola MM. Galantamine-Memantine Combination and Kynurenine Pathway Enzyme Inhibitors in the Treatment of Neuropsychiatric Disorders. Complex Psychiatry 2021;7:19-33. [PMID: 35141700 DOI: 10.1159/000515066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Gan J, Liu S, Chen Z, Wang XD, Ji Y. Effect of Multiple Medicines on Dementia Initial Treatment: Experience and Thinking. Am J Alzheimers Dis Other Demen 2021;36:15333175211053134. [PMID: 34841902 DOI: 10.1177/15333175211053134] [Reference Citation Analysis]
4 Roshandel Z, Norouzi S, Haghdoost MR, Fakhri A. Galantamine as Adjunctive Treatment for Ameliorating Negative Symptoms of Schizophrenia Patients. Jundishapur J Chronic Dis Care 2021;10. [DOI: 10.5812/jjcdc.114989] [Reference Citation Analysis]
5 Tanaka M, Tóth F, Polyák H, Szabó Á, Mándi Y, Vécsei L. Immune Influencers in Action: Metabolites and Enzymes of the Tryptophan-Kynurenine Metabolic Pathway. Biomedicines 2021;9:734. [PMID: 34202246 DOI: 10.3390/biomedicines9070734] [Cited by in Crossref: 59] [Cited by in F6Publishing: 67] [Article Influence: 59.0] [Reference Citation Analysis]
6 Nieto RR, Carrasco A, Corral S, Castillo R, Gaspar PA, Bustamante ML, Silva H. BDNF as a Biomarker of Cognition in Schizophrenia/Psychosis: An Updated Review. Front Psychiatry 2021;12:662407. [PMID: 34220575 DOI: 10.3389/fpsyt.2021.662407] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
7 Simeonova R, Zheleva D, Valkova I, Stavrakov G, Philipova I, Atanasova M, Doytchinova I. A Novel Galantamine-Curcumin Hybrid as a Potential Multi-Target Agent against Neurodegenerative Disorders. Molecules 2021;26:1865. [PMID: 33806197 DOI: 10.3390/molecules26071865] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
8 Annu, Baboota S, Ali J. Combination antipsychotics therapy for schizophrenia and related psychotic disorders interventions: Emergence to nanotechnology and herbal drugs. Journal of Drug Delivery Science and Technology 2021;61:102272. [DOI: 10.1016/j.jddst.2020.102272] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Koola MM. Alpha7 nicotinic-N-methyl-D-aspartate hypothesis in the treatment of schizophrenia and beyond. Hum Psychopharmacol 2021;36:1-16. [PMID: 32965756 DOI: 10.1002/hup.2758] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
10 Koola MM. Galantamine-Memantine combination in the treatment of Alzheimer's disease and beyond. Psychiatry Res 2020;293:113409. [PMID: 32829072 DOI: 10.1016/j.psychres.2020.113409] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
11 Fallah A, Mohanazadeh F, Safavi M. Design, synthesis, and in vitro evaluation of novel 1,3,4-oxadiazolecarbamothioate derivatives of Rivastigmine as selective inhibitors of BuChE. Med Chem Res 2020;29:341-55. [DOI: 10.1007/s00044-019-02475-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]